Log in | Register

Melissa Herkt Joins Emerson Process Management As President

For the latest pharmaceutical news and updates - Sign up now!
Loading...
Herkt brings extensive industry experience and strong leadership qualities to new corporate position
Emerson Process Management, an Emerson business, has announced the appointment of Melissa B. Herkt as president of Process Systems and Solutions - Americas. Herkt will lead the division created by Emerson to provide process improvement solutions to the life sciences, power, chemical, food and beverage, pulp and paper, and hydrocarbon and energy industries.

"Melissa has spent her entire career planning and delivering major projects in both the petrochemical and pharmaceutical industries," says Tom Snead, president, Systems and Solutions. "Her experience and leadership qualities are key to meeting the goals set for the Process Systems and Solutions division."

Herkt has been actively involved in global project management throughout her professional career. She has worked in the United States, the United Kingdom, France, Switzerland, Denmark, Norway, and Colombia and has conducted training in project management best practices at 66 locations in 21 countries. Her experience includes managing grassroots projects as large as $600 million and working on projects up to $3 billion in size.

Most recently Herkt was vice president of global project management for GlaxoSmithKline, where she was responsible for capital management, resource management, project manager training and development, project controls, project management standards, and the delivery performance of projects. She had previously worked for Hoffmann-La Roche, Exxon R&E, and Alabama Power Company.

Herkt holds a Bachelor of Science degree in civil engineering from Auburn University. She received the university's Civil Engineering Outstanding Alumna Award in 2004. Herkt is a member of the Board of Advisors for the Construction Industry Institute (CII) and co-chairs the CII Research Committee. She recently received the CII Outstanding Implementer Award for 2004. She serves on the Advisory Board of the University of Pittsburgh Mascaro Sustainability Initiative and is a member of the International Society of Pharmaceutical Engineers (ISPE).


Blogs

When Is Software The Answer To Regulatory Concerns About Your Investigations?

When Is Software The Answer To Regulatory Concerns About Your Investigations?

Jan 30 | John Ager, Technical Consultant, Life Science, Kepner-Tregoe, Inc

Document management software enables investigators to present the information used to reach conclusions clearly and concisely and it helps reviewers to track and approve investigations.

The Benefits of Professional Project Management

The Benefits of Professional Project Management

Jan 13 | Thorsten Vammen, Director at GEA Liquid Processing in Skanderborg, Denmark

Some companies feel that they can project manage new processing facilities themselves, bringing in sub-contracted help only when it’s needed. Self-managing is possible, but there may be a better way.

Multimedia

Government Seeking $1T Campaign Against Alzheimer's

Government Seeking $1T Campaign Against Alzheimer's

Jan 18 | Video

Government advisors tried to set priorities for a national campaign to treat and manage Alzheimer's disease, which is projected to cost more than a trillion dollars in care by 2050. But as Dr. Jon LaPook reports, the plan does not include any funding.

ADHD Drugs in Short Supply

ADHD Drugs in Short Supply

Jan 11 | Video

Parents of children with attention deficit disorders are forced to travel from pharmacy to pharmacy in search of prescription medicines with no guarantees they will be available.

Study: Link Between Statins And Diabetes

Study: Link Between Statins And Diabetes

Jan 10 | Video

A recent study reveals that women who take statins may have a greate chance of developing diabetes.

Avastin Shows Promise in Fight Against Ovarian Cancer

Avastin Shows Promise in Fight Against Ovarian Cancer

Jan 5 | Video

Two recent studies show that Avastin, already approved for other cancers - but still controversial, could help women buy more time in their fight against ovarian cancer.

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter